Modified Antibody-Drug Conjugate Site-Specific Linkage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates face challenges with low economic efficiency due to complex and costly site-specific conjugation methods, which affect their use as first-line therapeutic agents, and they often have variable drug conjugation yields and stability issues.
Innovation Solution
A modified antibody with a peptide motif including a metal ion-binding motif is used, allowing for site-specific drug conjugation with a higher yield and improved stability, enabling efficient production and targeted delivery of anticancer drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional site-specific conjugation methods are used, then drug conjugation specificity is improved, but production cost and complexity increase
Solution Approach 1:
The antibody is divided into functional regions with specific conjugation sites located in the Fc region, separating the binding function from the conjugation function. This allows independent optimization of each aspect and simplifies the overall conjugation process.
Solution Approach 2:
A peptide motif (ACGHA or AHGCA) acts as an intermediary element that mediates between the antibody and the cytotoxic drug. This motif provides a standardized conjugation interface, simplifying the conjugation method while maintaining specificity.
2Productivity
If conventional conjugation methods are used, then antibody-drug conjugate production is achieved, but conjugation yield is low and variable
Solution Approach 1:
The conjugation method utilizes specific chemical parameters (maleimide group reacting with cysteine thiol group) to achieve controlled and consistent conjugation. By optimizing these chemical parameters, high and reliable conjugation yield is achieved.
Solution Approach 2:
The peptide motif with cysteine residues is pre-introduced into the antibody Fc region before conjugation. This preliminary preparation ensures that the conjugation sites are ready and positioned optimally, leading to high and consistent conjugation yields.
3Quantity of substance
If multiple drugs are conjugated per antibody, then therapeutic efficacy is improved, but conjugate stability decreases
Solution Approach 1:
The Fc region of the antibody is designed with specific local properties (peptide motif containing cysteine residues) that are optimized for drug conjugation. This localized optimization allows multiple drugs to be conjugated while maintaining overall conjugate stability through controlled local chemistry.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified antibody-drug conjugate achieves enhanced in vivo anticancer effects with improved economic efficiency by increasing drug conjugation yield and maintaining antigen specificity, reducing production costs and stability concerns.
Implementation Method 1
a peptide motif including a metal ion-binding motif
Data Source
AI summary
The present disclosure relates to an antibody-drug conjugate in which a modified antibody comprising a motif having a specific structure at the end of the antibody is conjugated to a drug via a linker, and a composition comprising the same, and more particularly to a modified antibody-drug conjugate (mADC) comprising a modified antibody that has a significantly increased conjugation yield of drug due to a motif bound to the heavy chain or light chain C-terminus of the antibody, and to a composition comprising the same.